RFA
PDLI

Reilly Financial Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

Reilly Financial Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-500
Closed -$2K – 968
2016
Q3 		$2K Buy
+500
New +$1.59K ﹤0.01% 779
2015
Q4 		– Sell
-1,800
Closed -$9K – 1519
2015
Q3 		$9K Buy
1,800
+800
+80% +$4.58K ﹤0.01% 828
2015
Q2 		$6K Buy
+1,000
New +$6.7K ﹤0.01% 1042

Other funds holding PDLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Reilly Financial Advisors's PDLI Position: Q4 2016 in Review

Reilly Financial Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q4 2016, closing a stake of 500 shares — an estimated $2K sold.

Reilly Financial Advisors first reported a position in PDLI in Q2 2015 and held it in 3 quarters. The position peaked at $9K in Q3 2015. 190 funds tracked by Wall St. Rank hold PDLI as of Q4 2016.

  • Reilly Financial Advisors reported no remaining PDL BioPharma, Inc. position as of Q4 2016 after selling out during the quarter.
  • Reilly Financial Advisors sold 500 PDL BioPharma, Inc. shares in Q4 2016, an estimated $2K.
  • Reilly Financial Advisors first reported a position in PDL BioPharma, Inc. in Q2 2015 and held it in 3 quarters.
  • Reilly Financial Advisors's PDL BioPharma, Inc. position peaked at $9K in Q3 2015.
  • 190 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2016.

Based on Reilly Financial Advisors's 13F filing for Q4 2016, filed 24 Jan 2017.